For research use only. Not for therapeutic Use.
HMN-214 (Cat No.: I002261) is an orally bioavailable prodrug of HMN-176, a potent Polo-like kinase (PLK) inhibitor with antitumor activity. It disrupts mitotic progression and induces cell cycle arrest, leading to apoptosis in cancer cells. HMN-214 has been studied for its efficacy against various malignancies, including leukemia and solid tumors. By targeting PLK, a key regulator of cell division, it shows promise in overcoming chemoresistance. Its high specificity and bioavailability make it a valuable tool for oncology research and drug development.
| CAS Number | 173529-46-9 |
| Synonyms | N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide |
| Molecular Formula | C22H20N2O5S |
| Purity | ≥95% |
| Target | Polo-like Kinase (PLK) |
| Solubility | 10 mM in DMSO |
| Storage | 3 years -20C powder |
| IC50 | 0.12 μM |
| IUPAC Name | N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide |
| InChI | 1S/C22H20N2O5S/c1-17(25)24(30(27,28)21-11-9-20(29-2)10-12-21)22-6-4-3-5-19(22)8-7-18-13-15-23(26)16-14-18/h3-16H,1-2H3/b8-7+ |
| InChIKey | OCKHRKSTDPOHEN-BQYQJAHWSA-N |
| SMILES | CC(=O)N(C1=CC=CC=C1/C=C/C2=CC=[N+](C=C2)[O-])S(=O)(=O)C3=CC=C(C=C3)OC |
| Reference | </br>1:A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD.Clin Cancer Res. 2006 Sep 1;12(17):5182-9. PMID: 16951237 Free Article</br>2:In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Takagi M, Honmura T, Watanabe S, Yamaguchi R, Nogawa M, Nishimura I, Katoh F, Matsuda M, Hidaka H.Invest New Drugs. 2003 Nov;21(4):387-99. PMID: 14586206 </br>3:HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H.Cancer Res. 2003 Oct 15;63(20):6942-7. PMID: 14583495 Free Article |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
